Combination Of A Natural Compound (Baicalein) And Paclitaxel Results In Synergistic Apoptosis In Mouse Breast Cancer Cells

Akmal, Yasir; Senthil, Maheswari; Yan, Jin; Xing, Q.; Wang, Y.; Yim, John H.

doi:10.1016/j.jss.2010.11.560

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…46 Therefore, combination therapy with PTX and BCL will have a synergistically enhanced antitumor effect due to the combining of the anticancer mechanisms of each drug. 47 Overexpression of B-cell lymphoma, 48 IL-6, 49 and CDK-1 50 has been shown to inhibit PTX-induced apoptosis and result in MDR. Therefore, the mentioned antitumor mechanisms of BCL can inhibit the drug resistance of PTX.…”

Section: Introductionmentioning

confidence: 99%

Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo

Wang¹,

Xi²,

Duan³

et al. 2015

IJN

View full text Add to dashboard Cite

Purpose Combination anticancer therapy is promising to generate synergistic anticancer effects to maximize the treatment effect and overcome multidrug resistance. The aim of the study reported here was to develop multifunctional, dual-ligand, modified, self-assembled nanoparticles (NPs) for the combination delivery of baicalein (BCL) and paclitaxel (PTX) prodrugs. Methods Prodrug of PTX and prodrug of BCL, containing dual-targeted ligands of folate (FA) and hyaluronic acid (HA), were synthesized. Multifunctional self-assembled NPs for combination delivery of PTX prodrug and BCL prodrug (PTX-BCL) were prepared and the synergistic antitumor effect was evaluated in vitro and in vivo. The in vitro transfection efficiency of the novel modified vectors was evaluated in human lung cancer A549 cells and drug-resistant lung cancer A549/PTX cells. The in vivo antitumor efficiency and systemic toxicity of different formulations were further investigated in mice bearing A549/PTX drug-resistant human lung cancer xenografts. Results The size of the PTX-BCL NPs was approximately 90 nm, with a positive zeta potential of +3.3. The PTX-BCL NPs displayed remarkably better antitumor activity over a wide range of drug concentrations, and showed an obvious synergism effect with CI 50 values of 0.707 and 0.513, indicating that double-ligand modification and the co-delivery of PTX and BCL prodrugs with self-assembled NPs had remarkable superiority over other formulations. Conclusion The prepared PTX-BCL NP drug-delivery system was proven efficient by its targeting of drug-resistant human lung cancer cells and delivering of BCL and PTX prodrugs. Enhanced synergistic anticancer effects were achieved by PTX-BCL NPs, and multidrug resistance of PTX was overcome by this promising targeted nanomedicine.

show abstract